Versant Capital Management
PCVX icon

Versant Capital Management’s Vaxcyte PCVX Stock Holding History

Versant Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$42.9K Buy
754
+1
+0.1% +$58 ﹤0.01% 1505
2026
Q2 		$43.8K Sell
753
-95
-11% -$5.16K ﹤0.01% 1452
2026
Q1 		$49.3K Buy
848
+414
+95% +$22.5K ﹤0.01% 1255
2025
Q4 		$20K Buy
434
+7
+2% +$313 ﹤0.01% 1638
2025
Q3 		$15.4K Sell
427
-1,587
-79% -$52.6K ﹤0.01% 1723
2025
Q2 		$65.5K Buy
2,014
+1,851
+1,136% +$60.7K 0.01% 846
2025
Q1 		$6.16K Buy
163
+71
+77% +$5.68K ﹤0.01% 1948
2024
Q4 		$7.53K Buy
92
+74
+411% +$7.35K ﹤0.01% 1546
2024
Q3 		$2.06K Buy
+18
New +$1.62K ﹤0.01% 1555
2023
Q3 		– Sell
-9
Closed -$449 – 2022
2023
Q2 		$449 Buy
+9
New +$427 ﹤0.01% 1860

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Versant Capital Management's PCVX Position: Q3 2026 in Review

Versant Capital Management increased its Vaxcyte (PCVX) stake by 0.13% in Q3 2026, buying an estimated $58 and bringing the position to 754 shares worth $42.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1505.

Versant Capital Management first reported a position in PCVX in Q2 2023 and has held it in 10 quarters since. The position peaked at $65.5K in Q2 2025. 167 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • Versant Capital Management held 754 shares of Vaxcyte worth $42.9K as of Q3 2026.
  • Versant Capital Management bought 1 Vaxcyte share in Q3 2026, an estimated $58.
  • Vaxcyte made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1505 holding.
  • Versant Capital Management first reported a position in Vaxcyte in Q2 2023 and has held it in 10 quarters since.
  • Versant Capital Management's Vaxcyte position peaked at $65.5K in Q2 2025.
  • 167 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.